Whither CAR T? will the FDA being under the hood and the availability of bispecifics make these therapies less attractive?
Sang ChaoJustin TseAmy VanGalderGarrick WongTerra WonsettlerAndrew HertlerPublished in: The American journal of managed care (2024)